The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.
Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.
The English language version is always the official and authoritative version of this website.
NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.
Synopsis As Introduced Amends the Pharmacy Practice Act of 1987. Prohibits drug product selection in refills of anti-epileptic drugs without notification and the documented consent of the prescriber and patient or the participating provider. Effective immediately.
Adds a provision declaring the Section concerning the prohibition of anti-epileptic drug product selection necessary for the immediate preservation of the public peace, health, and safety. Makes changes to the definition of "anti-epileptic drug" and "epilepsy". Defines "seizure" and removes the definition of "refill". Removes the provision concerning drug product selection in the refill of a prescription for anti-epileptic drugs and the provision concerning the determination of anti-epileptic drug therapy for an enrollee by a participating provider. Prohibits a pharmacist from interchanging an anti-epileptic drug or formulation of an anti-epileptic drug (instead of an equivalent anti-epileptic drug) for the treatment of epilepsy without notification and the documented consent of the prescribing physician and the patient or the patient's parent, legal guardian, or spouse (instead of the prescriber and patient) when the prescribing physician has indicated on the original prescription "dispense as written" or "may not substitute". Amends the Illinois Food, Drug and Cosmetic Act to exclude product selection of anti-epileptic drugs from a provision concerning the interchange of different brands of the same generically equivalent drug product.
This site is maintained for the Illinois General Assembly
by the Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706
Contact ILGA Webmaster